Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ET

Company Participants

Warren Huff - Chairman and Chief Executive Officer

Dawn Bir - Executive Vice President and Chief Commercial Officer

Andrea Loewen - Senior Vice President of Global Regulatory Affairs

Seemi Khan - Senior Vice President and Chief Medical Officer

Colin Meyer - Executive Vice President and Chief Innovation Officer

Manmeet Soni - President, Chief Operating Officer and Chief Financial Officer

Conference Call Participants

Yigal Nochomovitz - Citigroup

Madhu Kumar - Goldman Sachs

Yatin Suneja - Guggenheim Securities

Charles Duncan - Cantor Fitzgerald

Carter Gould - Barclays

Annabel Samimy - Stifel

Maury Raycroft - Jefferies

Matthew Kaplan - Ladenburg Thalmann

Operator

Thank you for standing by, and welcome to the Reata Pharmaceuticals First Quarter Financial Results Update on Operational Progress and Development Programs Conference Call. An audio recording of today’s webcast will be available shortly after the call in the Investor section of Reata’s website at reatapharma.com.

Before the Company proceeds with its remarks, please note the forward-looking statements disclosure in the Company’s press release. There are many factors that could cause results to differ from expectations, including those noted in the Company’s SEC filings. Today’s statements are not guarantees of future outcomes.

Please also note that any comments made on today’s call apply only as of today, May 10, 2023, and may no longer be accurate at the time of any webcast replay or transcript rereading. Following the prepared remarks, we will open the call up for questions. [Operator Instructions]

We are joined today by Warren Huff, Reata’s Chief Executive Officer; Manmeet Soni, President; Colin Meyer, Chief Innovation Officer; Dawn Bir, Chief Commercial Officer; Seemi Khan, Chief Medical Officer; and Andrea Loewen, Senior Vice President, Regulatory Affairs.

At this time, I would like to turn the call over to Warren Huff.

Warren Huff

Good morning, everyone. We thank you for joining us today.

I’ll begin on Slide 4. On February the 28th, we announced that the FDA approved SKYCLARYS as the first and only FDA approved drug indicated for the treatment of Friedreich’s ataxia or FA, an adults and adolescents aged 16 years and older.

As Dawn Bir will share later in the call, our experienced and fully trained teams began engaging customers immediately following approval. We are pleased to share that we have seen strong initial demand for SKYCLARYS from patients and their healthcare providers.